European Companies Search Engine

Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Glaxosmithkline Research & Development Ltd., London

Watch
Glaxosmithkline Research & Development Ltd.

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Premium Service
Unlock Dossier
What is a Dossier?
A dossier provides comprehensive company details as a PDF, together with all underlying original publications and original data in one place.
The download feature is exclusively available for our paid plan. Upgrade your account to access:
Quick Dossier
Entire company details as a PDF
Power Dossier
Entire company details along with all original publications / original data bundled in a ZIP file
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more
Learn more
View plans

Name

Glaxosmithkline Research & Development Ltd.
Glaxo Research and Development Ltd.
Glaxo Group Research Ltd.
Matburn Research Ltd.

Identification

Chp
Companies House 00835139
Sirul
Siren 940414337
Siret
Siret 94041433700011
Lei
5493003EJXH8XA8L9095

Address

79 New Oxford Street, London WC1A 1DG, United Kingdom
980 Great West Road Brentford Middlesex, United Kingdom

Corporate purpose

72.19
Other research and experimental development on natural sciences and engineering

The company's activity is the movement of own assets, mainly from Ireland to France. GSK R&D UK focuses on the development of vaccines and medicines in four main therapeutic areas: infectious diseases, HIV, pulmonology/immunology and oncology. She also investigates opportunities for organic research and commercial development in other therapeutic areas, where there is a need for patients and a focus on human genetics, genomics, and immune system science.

Financial performance

Earnings

For this company, Earnings numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Revenue

For this company, Revenue numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Employees

For this company, Employees numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Persons

Marketing & Tech

Network

Loading network

Legal Structure

Current legal representatives Legal form information Premium
Premium
5Director
1Secretary
2Director
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

JOBS AT NORTH DATA

  • Modern Java Developer
Ownership relations Premium + Ownership & Flags add-on
Premium + Ownership & Flags add-on
Shareholders and Investors
One known shareholder
Portfolio and Investments
One known active shareholding
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Financials

Key Performance Indicators Financial · Mktg & Tech Premium
Premium
Base/share capital
Total assets
Earnings
Earnings CAGR
Revenue
Revenue CAGR
Return on sales
Equity
Equity ratio
Return on equity
Employee number
Revenue per employee
Taxes
Tax ratio
Receivables
Liabilities
Wages and salaries
Average salaries per employee
Pension provisions
Number of public fundings
Total public funding
Upgrade to unlock all features

Premium plans starting from €49/month

Learn more View plans
Learn more View plans

Publications

Year 2026 in Hor
5 EU fundings (€0.00): Driving Sustainable Innovation to Minimise PFAS in European Healthcare …
10 Aug 2026 also 10/10/2016, 25/09/2015, 03/10/2014, 12/07/2013, 09/07/2012, 08/08/2011, 16/06/2010, 29/05/2009, 14/08/2008, 19/10/2007, 22/09/2006, 07/04/2005
Full accounts made up to 2025-12-31
20 Apr 2026 also 30/07/2025, 15/08/2024, 18/08/2022, 10/08/2021, 25/08/2020, 29/08/2019, 21/08/2018, 15/08/2017
Confirmation statement made with no updates
1 Jan 2026 in Fts
EU funding (€4,895,668): 101253015 - Guide-AI - Guide-AI Guiding Your Treatment with Current Evidence
1 Dec 2025 in Fts
EU funding (€14M): 101219324 - Probe - Patient Relevant Osteoarthritis Endpoints Using BIG Data Evaluation
1 Dec 2025 via Ablynx N.V.
EU funding: Patient Relevant Osteoarthritis endpoints using Big data Evaluation
14 Aug 2025
Annual report for the year ending 31/12/2024
1 May 2025 in Fts
EU funding (€13.3M): 101191967 - Greg - Testing, Improving, and CO-Creating Guidance and Tools for Real World Evidence Generation in Europe and USE for Decision-Making in Europe: Greg
1 May 2025 via Actelion Pharmaceuticals Ltd.
EU funding: Testing, improving, and co-creating Guidance and Tools for Real World Evidence Generation in Europe and use for Decision-Making in Europe: GREG
1 Mar 2025 in France
Name: GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED
1 Feb 2025 in France
Reg­is­tra­tion: 01/02/2025 · Address · Legal form: Société étrangère non immatriculée au RCS · Name: GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED · Segment clas­si­fi­ca­tion
Year 2024 in Hor
9 EU fundings (€0.00): Research in Europe and Diversity Inclusion …
24 Sept 2024
Secretary's details changed for Victoria Whyte
23 Sept 2024
Director's details changed for Dr Kaivan Khavandi · Director's details changed for Mr Christopher David George Pickering
20 Sept 2024
Director's details changed for Mrs Demet Gurunlu Russ
17 Sept 2024
Director's details changed for Mr Graham Paul Rivers · Director's details changed for Mr Aidan Lynch …
11 Sept 2024
Address
29 Aug 2024
Director: Aidan Lynch
14 Aug 2024
Annual report for the year ending 31/12/2023
18 Jul 2024
Address
12 Jul 2024
Appointment of Mrs Demet Gurunlu Russ as a director
5 Jul 2024
No longer Director: Jill Dawn Anderson
23 May 2024
Director: Kaivan Khavandi, Ch. D. G. Pickering
10 May 2024
No longer Director: David George Allen
26 Sept 2023
Director: Graham Paul Rivers · No longer Director: Audra Jane Halsey
16 Aug 2023
Annual report for the year ending 31/12/2022
16 Aug 2023
Director's details changed for Glaxo Group Limited
10 Aug 2023
Companies House - Filing
3 Mar 2023
Director: Jill Dawn Anderson
2 Mar 2023
No longer Director: Jerome Andries
13 Oct 2022
Annual report for the year ending 31/12/2021
6 Jun 2022
Resolution of adoption of Articles of Association (ADOPT ARTICLES) · Memorandum and Articles of Association …
14 Oct 2021 in Hor
EU funding: FrAmework for ClInicaL trIal participants daTA reutilization for a fully Transparent and Ethical ecosystem
4 Oct 2021
Annual report for the year ending 31/12/2020
17 Mar 2021
Director: Audra Jane Halsey
8 Sept 2020
Annual report for the year ending 31/12/2019
Year 2020 in Hor
8 EU fundings (€0.00): Prioritisation and Risk Evaluation of Medicines in the EnviRonment …
Year 2019 in Hor
18 EU fundings (€171,798): Collaboration for Prevention and Treatment of MDR Bacterial Infections …
9 Oct 2019
Annual report for the year ending 31/12/2018
Year 2018 in Hor
12 EU fundings (€606,345): Multiphoton Microscopy and Ultrafast Spectroscopy: Imaging meets Quantum …
4 Oct 2018
Annual report for the year ending 31/12/2017
23 Apr 2018
Director: Jerome Andries
12 Sept 2017
Annual report for the year ending 31/12/2016
Year 2017 in Hor
8 EU fundings (€0.00): Rheuma Tolerance for Cure …
19 Dec 2016 in Hor
EU funding (€323,750): INternational Smart Collaborative Open-access hybrid Printed Electronics pilot line
23 Sept 2016 as Glaxosmithkline Research and Development Ltd.
EU funding (€3,827,031): Directed Protein Evolution for Synthetic Biology and Biocatalysis
22 Aug 2016
Confirmation statement made with updates
1 Aug 2016 in Ukri
UK funding (£215,173): RaSTA (Rapid Sterility Testing Approach)
1 Apr 2016 in Hor
EU funding (€77,281): Graphene-based disruptive technologies
1 Feb 2016
No longer Director (1)
30 Dec 2015
Director: David George Allen
Year 2015 in Hor
10 EU fundings (€994,076): Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes – Sofia ref.: 115797 …
10 Sept 2015
Director (1)
9 Sept 2015
No longer Director (1)
27 Aug 2015
Capital: £600M
18 Aug 2014
Capital: £600M
1 Sept 2013 in Fts
EU funding: Earip
28 Aug 2013
Capital: £600M
20 Feb 2013
No longer Director (1)
15 Feb 2013
Director (1)
14 Sept 2012 also 20/09/2010
Annual return made up to 2012-08-15 with full list of shareholders
1 Jan 2012 in Fts
EU funding (€269,050): Novel Statistical Methodology for Diagnostic/Prognostic and Therapeutic Studies and Systematic Reviews
1 Dec 2011 in Fts
EU funding (€15,000.00): Developing a Global Understanding of the PRC and NuRD Complexes in Stem Cell Differentiation, in Health and Disease
6 Oct 2011
Director's details changed for Edinburgh Pharmaceutical Industries Limited · Director's details changed for Glaxo Group …
30 Aug 2011
Secretary: Victoria Whyte
19 Aug 2011
Annual return made up to 2011-08-15 with full list of shareholders · Director's details changed for Glaxo Group Limited
18 Aug 2011
Director's details changed for Edinburgh Pharmaceutical Industries Limited
14 Apr 2011
Re-agreement 11/04/2011
3 Mar 2011
No longer Secretary (1)
6 Oct 2010
Annual return made up to 2010-08-16 with full list of shareholders
21 Sept 2010
Director (1)
15 Sept 2010
No longer Director (1)
1 Jan 2010 in Fts
EU funding: Methods in Neuroimaging
1 Dec 2009 in Fts
EU funding: Synapses: From Molecules to Higher Brain Function and Diseases
18 Aug 2009 also 11/09/2008, 02/11/2007, 11/09/2006
Return made up to 15/08/09; full list of members
1 Dec 2008 in Fts
EU funding (€2,599.72): Plasticise
5 Mar 2008
Director's change of particulars / N.N. / 04/02/2008
22 Jun 2007 in Fts
EU funding: The Impact of Insulin Resistance on Neural Stem Cells in Models of Alzheimer's Disease
14 Feb 2006
Secretary's particulars changed
6 Sept 2005
Return made up to 15/08/05; full list of members · Director's particulars changed
There are no publications matching your search.

Mentions

26 Oct 2026 in Ler
Direct parent
26 Oct 2026 in Ler
Ultimate parent
15 Oct 2026 in Psc
Voting rights: Stevenage Bioscience Catalyst
27 Sept 2026 in Rne
Reg­is­tra­tion: 01/02/2025 · Companies · Segment clas­si­fi­ca­tion · Corporate Purpose
9 Jul 2024 in Ler
Direct parent
There are no publications matching your search.

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Printing is only available to North Data premium service subscribers.